Reference Standard (RS) in Bioequivalence Studies

by

Introduction

In pharmaceutical development, a Reference Standard (RS), often referred to as a Reference Listed Drug (RLD) or comparator product, is a benchmark for evaluating the performance of generic drugs in bioequivalence (BE) studies. The RS ensures that generic drugs meet therapeutic equivalence standards, a critical step for regulatory approval.

What is a Reference Standard?

An RS is an approved drug product used in BE studies to compare the pharmacokinetics equivalence of a generic drug. It can either be:

  • Reference Listed Drug (RLD): The original innovator product approved by regulatory authorities like the USFDA.
  • Comparator Product: A drug approved in stringent markets, often used when the RLD is unavailable.
  • Purpose of RS in BE Studies
  • Bioequivalence: Confirms the generic and RS release the same amount of active ingredient into the body
  • Regulatory Compliance: Aligns with the approval requirements of agencies like the USFDA, EMA, and WHO.

Steps in Reference Standard Evaluation

Selection of RS

Regulatory Requirements:

  • USFDA: Use the RLD listed in the Orange Book.
  • EMA/WHO: Use a comparator product approved in stringent markets or listed by WHO.

Key Criteria:

  • Match in dosage form, strength, and route of administration.

Procurement of RS

  • Source: Obtain RS from licensed distributors

Documentation:

  • Batch and lot numbers, expiry dates, and CoA.

Analytical Characterization of RS

Comprehensive testing ensures the RS’s reliability for BE studies:

Identity Confirmation:

  • Techniques: FTIR, UV-Vis, NMR, or Mass Spectrometry.

Assay and Potency:

  • Methods: HPLC or titration to verify active ingredient concentration.

Impurity Profiling:

  • Use HPLC or LC-MS to identify impurities per ICH Q3 guidelines.

Dissolution Testing:

  • Establish dissolution profiles in acidic, neutral, and alkaline media.
  • Compare test and RS profiles using the Similarity Factor (f2).

Physical Properties:

  • Evaluate hardness, friability, and particle size distribution.

Regulatory Guidelines

USFDA:

  • RLD must match the Orange Book listing.
  • Justify the use of alternative RS if the RLD is unavailable.

EMA:

  • Accepts comparator products approved in the EU or equivalent stringent markets.

WHO:

  • Permits comparator products from WHO prequalified lists or other approved sources.

Importance of RS in BE Studies

  • Consistency: Provides a reliable benchmark.
  • Compliance: Meets global regulatory standards.
  • Patient Safety: Confirms the safety and efficacy of generic drugs.

Conclusion

RS is a cornerstone of bioequivalence studies. Its selection, characterization, and use are critical for ensuring generic drugs meet the same safety, efficacy, and quality standards as innovator products. Following regulatory guidelines and thorough documentation helps pharmaceutical companies achieve global approvals and ensure patient access to high-quality generics.


Read also:


Resource Person: Moinuddin syed. Ph.D, PMP

Leave a Comment